Member access

4-Traders Homepage  >  Shares  >  OTC Bulletin Board  >  CELLCEUTIX    CTIX   US15115V1017

CELLCEUTIX (CTIX)

0
SummaryNewsCompany 
News SummaryMost relevantAll news 

Cellceutix Corp : Small Cap Stocks in Focus Today are CTIX, CWGL, FNRC and DEWM

10/29/2013 | 12:50am US/Eastern

Cellceutix (OTC: CTIX),The Crimson Wine Group (OTC: CWGL), 1st NRG Corp. (PINK: FNRC) and Dewmar International BMC, Inc. (OTC: DEWM) are our Small Cap Stocks in focus today.

Cellceutix (OTC: CTIX) is a clinical stage biopharmaceutical company developing and commercializing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its existing portfolio of clinical compounds and strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Kevetrin in the laboratory has been shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

For our complete article on CTIX please go here: http://tinyurl.com/otcmagic-cellceutix

The Crimson Wine Group (OTC: CWGL) owns and operates boutique, estate-based wineries that produce world class wines in the finest wine growing regions of California, Oregon and Washington. With a commitment to the preeminent appellations and vineyard sites of each region, a philosophy of hand-crafted quality and with the highest respect for the land, each CWG property produces distinct varietal wines that reflect the finest characteristics of their place of origin.

For our complete article on CWGL please go here: http://tinyurl.com/otcmagic-crimson

1st NRG Corp. (PINK: FNRC) is an exploration and production company headquartered in Denver, Colorado whose activity to date has been centered on development of the Clabaugh Ranch Field, a project developing and producing coal bed methane reserves (CBM) located in the Powder River Basin of Wyoming.

On October 21 FNRC announced a New Drilling and Production Revenues for CBM Properties in Wyoming

For our complete article on FNRC please go here: http://tinyurl.com/otcmagic-fnrc

Dewmar International BMC, Inc. (OTC: DEWM) is a U.S. based new product development, manufacturing and brand management company. Established in 2003, Dewmar's primary business strategy has been in creating high profit margins with functional foods and beverages. The Company's flagship product, Lean Slow Motion Potion, whose flavors include Yella, Purp and Easta Pink, is rated as one of the top 3 national selling relaxation beverages in the U.S. market. The company has offices in Clinton, MS; Las Vegas, NV and Houston, TX.

For our complete article on DEWM please go here: http://tinyurl.com/otcmagic-dewm

OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.

Subscribe Here: http://www.otcmagic.com/

Contact Info:

OTCMagic
info@otcmagic.com


© Accesswire 2013
Latest news on CELLCEUTIX
6h ago CELLCEUTIX : New Chief Operating Officer Dr. James Alexander Addresses Sharehold..
10/24 CELLCEUTIX : Change in Directors or Principal Officers, Regulation FD Disclosure..
10/23 CELLCEUTIX : Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single..
10/13 CELLCEUTIX : Investigational New Drug (IND) Application Becomes Effective, Selec..
09/24 CELLCEUTIX : Other Events, Financial Statements and Exhibits (form 8-K)
09/24 CELLCEUTIX : Provides Update to Shareholders
09/24 CELLCEUTIX : Rolls Out Update on Phase 2b Study for Brilacidin
09/19 CELLCEUTIX : to President Obama: We Have the Tools and Will Rise Up to the Chall..
09/15 CELLCEUTIX : MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPER..
09/15 CELLCEUTIX : Releases Update on Phase 2b Study for Brilacidin
Advertisement
Dynamic quotes  
ON
| OFF